Bionano files $30M IPO to fund its long base pair DNA sequencers

Nasdaq
The company says its Saphyr system challenges other next-generation devices at sequencing longer molecules, and in detecting larger structural variations. (Nasdaq)

DNA analyzer manufacturer Bionano Genomics filed for a $30 million IPO, with plans to expand its commercial operations and potentially establish a direct commercialization foothold in China. It plans to use the Nasdaq symbol BNGO.

The San Diego-based company says its Saphyr system challenges Illumina’s and other next-generation devices at sequencing longer molecules, and in detecting larger, possibly missed structural variations in genetic material, ranging from 500 to over 500,000 base pairs for certain deviations.

Bionano’s devices are currently only available for research use only, but the company plans to pursue regulatory approvals or clearances in areas outside of life science research, potentially in the realm of laboratory-developed tests, the company said in its prospectus filed in June.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Bionano had originally planned an offering of the same $30 million total, but with a larger price range per share, at $8 to $10, for 3.4 million shares. It now plans to offer 5.5 million shares at $5 to $6, according to Renaissance Capital, which said the company will have decreased its market value by 21% to $85 million, down from $108 million.

The company's investors include Novartis’ venture capital arm, which participated in a 2016 series D round.

RELATED: Illumina’s stock rides wave of high demand for genomic sequencing

This past week, Illumina posted record quarterly revenues driven by the high demand for genomic sequencing in the research industry. Its $830 million haul was buoyed by sales of consumable chips and cells used in its DNA analyzers.

In its prospectus, Bionano cited a Research and Markets report that estimated the worldwide market for genomics products and services is expected to grow to about $23.9 billion by 2022, up from about $14.7 billion in 2017.

Suggested Articles

The FDA has approved its first contact lens designed to effectively slow the progression of nearsightedness in children, starting in ages 8 to 12.

Novartis tapped Biofourmis to develop tracking programs for heart failure patients, as the latter acquired Biovotion, makers of clinical wearables.

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.